DelveInsight’s, “Metastatic Castration-Resistant Prostate Cancer Pipeline Insights 2025” report provides comprehensive insights about 75+ companies and 75+ pipeline drugs in the Metastatic Castration-Resistant Prostate Cancer pipeline landscape. It covers the Metastatic Castration-Resistant Prostate Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Metastatic Castration-Resistant Prostate Cancer therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight’s comprehensive Metastatic Castration-Resistant Prostate Cancer Pipeline Report to explore emerging therapies, key Metastatic Castration-Resistant Prostate Cancer Companies, and future Metastatic Castration-Resistant Prostate Cancer treatment landscapes @ Metastatic Castration-Resistant Prostate Cancer Pipeline Outlook Report
Key Takeaways from the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
- In August 2025, Novartis Pharmaceuticals announced a Phase II study aims to evaluate the efficacy and safety of the combination of JSB462 (also known as luxdegalutamide) at 100 mg and 300 mg QD doses + lutetium (177Lu) vipivotide tetraxetan (hereafter referred as AAA617) compared with AAA617 (control) in participants with metastatic Castration Resistant Prostate Cancer (mCRPC) with prior exposure to at least 1 Androgen Receptor Pathway Inhibitor (ARPI) and 0-2 taxane regimens and to select the recommended dose of the combination for phase III. Towards that end, the totality of the efficacy, safety, tolerability and pharmacokinetic (PK) data from participants randomized in the study will be evaluated.
- In August 2025, Pfizer announced a study will explore whether a combination of the investigational drug PF-06821497 and enzalutamide will work better than taking enzalutamide alone in participants with mCRPC who are ARSi or abiraterone naïve.
- In August 2025, Amgen conducted a study is to compare overall survival in participants receiving xaluritamig versus investigator’s choice (cabazitaxel or second androgen receptor-directed therapy [ARDT]).
- In August 2025, Merck Sharp & Dohme LLC announced a study is to assess the safety and efficacy of pembrolizumab (MK-3475) combination therapy in participants with metastatic castration resistant prostate cancer (mCRPC). There will be ten cohorts in this study: Cohort A will receive pembrolizumab + olaparib, Cohort B will receive pembrolizumab + docetaxel + prednisone, Cohort C will receive pembrolizumab + enzalutamide, Cohort D will receive pembrolizumab + abiraterone + prednisone Cohort E will receive pembrolizumab+lenvatinib, Cohort F will receive pembrolizumab+lenvatinib, Cohort G will receive pembrolizumab/vibostolimab coformulation (MK-7684A), Cohort H will receive pembrolizumab/vibostolimab coformulation, Cohort I will receive pembrolizumab+carboplatin+etoposide in Arm 1 and carboplatin+etoposide in Arm 2 and Cohort J will receive belzutifan in Arm1 and Pembrolizumab+belzutifan in Arm 2. Outcome measures will be assessed individually for each cohort.
- In August 2025, AstraZeneca organized a study is to evaluate the efficacy and safety of Olaparib compared with standard of care (Enzalutamide or Abiraterone Acetate) in Chinese men with metastatic castration-resistant prostate cancer who have failed prior treatment with a new hormonal agent and have BRCA1/2 mutations.
- DelveInsight’s Metastatic Castration-Resistant Prostate Cancer pipeline report depicts a robust space with 75+ active players working to develop 75+ pipeline therapies for Metastatic Castration-Resistant Prostate Cancer treatment.
- The leading Metastatic Castration-Resistant Prostate Cancer Companies such as Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
- Promising Metastatic Castration-Resistant Prostate Cancer Therapies such as JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
Discover how the Metastatic Castration-Resistant Prostate Cancer treatment paradigm is evolving. Access DelveInsight’s in-depth Metastatic Castration-Resistant Prostate Cancer Pipeline Analysis for a closer look at promising breakthroughs @ Metastatic Castration-Resistant Prostate Cancer Clinical Trials and Studies
Metastatic Castration-Resistant Prostate Cancer Emerging Drugs Profile
- SRF617: Surface Oncology
SRF617 is a fully human antibody designed to inhibit the enzymatic activity of CD39 in the tumor microenvironment, allowing for a dual mechanism of action to promote anti-tumor immunity via reduction of immunosuppressive adenosine in addition to increasing levels of immunostimulatory ATP. SRF617 has been granted Orphan Drug designation for the treatment of advanced pancreatic cancer by the FDA.
- Rucaparib: Clovis Oncology
Rucaparib is an oral, small molecule inhibitor of PARP1, PARP2 and PARP3 being developed in multiple tumor types, including ovarian and metastatic castration-resistant prostate cancers, as monotherapy, and in combination with other anti-cancer agents. Exploratory studies in other tumor types are also underway.
- HP518: Hinova Pharmaceuticals
HP518, a highly selective and orally bioavailable chimeric degrader targeting androgen receptor (AR) with the potential to overcome the drug resistance of prostate cancer due to some specific AR mutations. In discovery and preclinical studies, HP518 showed high degradation activity against wild type AR and some specific AR mutants that are resistant to enzalutamide, and excellent antitumor activity in xenograft mouse models. HP518 is highly selective for AR.
The Metastatic Castration-Resistant Prostate Cancer pipeline report provides insights into
- The report provides detailed insights about companies that are developing therapies for the treatment of Metastatic Castration-Resistant Prostate Cancer with aggregate therapies developed by each company for the same.
- It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Metastatic Castration-Resistant Prostate Cancer Treatment.
- Metastatic Castration-Resistant Prostate Cancer Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
- Metastatic Castration-Resistant Prostate Cancer Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
- Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Metastatic Castration-Resistant Prostate Cancer market.
Get a detailed analysis of the latest innovations in the Metastatic Castration-Resistant Prostate Cancer pipeline. Explore DelveInsight’s expert-driven report today! @ Metastatic Castration-Resistant Prostate Cancer Unmet Needs
Metastatic Castration-Resistant Prostate Cancer Companies
Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
Metastatic Castration Resistant Prostate cancer pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.
- Oral
- Intravenous
- Subcutaneous
Metastatic Castration-Resistant Prostate Cancer Products have been categorized under various Molecule types such as
- Small molecule
- Cell Therapy
- Peptides
- Polymer
- Small molecule
- Gene therapy
Download DelveInsight’s latest report to gain strategic insights into upcoming Metastatic Castration-Resistant Prostate Cancer Therapies and key Cervical Cancer Developments @ Metastatic Castration-Resistant Prostate Cancer Market Drivers and Barriers, and Future Perspectives
Scope of the Metastatic Castration-Resistant Prostate Cancer Pipeline Report
- Coverage- Global
- Metastatic Castration-Resistant Prostate Cancer Companies- Surface Oncology, Regeneron Pharmaceuticals, Clovis Oncology, AstraZeneca, Veru Healthcare, Hinova Pharmaceuticals, Zenith Epigenetic, Eli Lilly and Company, Lantern Pharma, Astellas Pharma/Seagen, Pfizer, Progenics Pharmaceutical, Molecular Insight Pharmaceuticals, Bayer, Accutar Biotechnology Inc, Hinova Pharmaceuticals, Taiho Oncology, Inc., Forma Therapeutics, Inc., Dizal Pharmaceuticals, Amgen, and others.
- Metastatic Castration-Resistant Prostate Cancer Therapies- JNJ-78278343, Cetrelimab, Cabazitaxel, TVB-2640, Enzalutamide, Abiraterone acetate, JNJ-56021927, Xofigo (Radium-223 dichloride, BAY88-8223), and others.
- Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
- Metastatic Castration-Resistant Prostate Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Metastatic Castration-Resistant Prostate Cancer drug development? Find out in DelveInsight’s exclusive Metastatic Castration-Resistant Prostate Cancer Pipeline Report—access it now! @ Metastatic Castration-Resistant Prostate Cancer Emerging Drugs and Major Companies
Table of Contents
- Introduction
- Executive Summary
- Metastatic Castration Resistant Prostate Cancer: Overview
- Pipeline Therapeutics
- Therapeutic Assessment
- Metastatic Castration Resistant Prostate Cancer– DelveInsight’s Analytical Perspective
- Late Stage Products (Phase III)
- Rucaparib: Clovis Oncology
- Drug profiles in the detailed report…..
- Mid Stage Products (Phase II)
- Surface Oncology: SRF 617
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I/II)
- REGN 4336: Regeneron Pharmaceuticals
- Drug profiles in the detailed report…..
- Early Stage Products (Phase I)
- HP 518: Hinova Pharmaceuticals
- Drug profiles in the detailed report…..
- Inactive Products
- Metastatic Castration Resistant Prostate cancer Key Companies
- Metastatic Castration Resistant Prostate cancer Key Products
- Metastatic Castration Resistant Prostate cancer- Unmet Needs
- Metastatic Castration Resistant Prostate cancer- Market Drivers and Barriers
- Metastatic Castration Resistant Prostate cancer- Future Perspectives and Conclusion
- Metastatic Castration Resistant Prostate cancer Analyst Views
- Metastatic Castration Resistant Prostate cancer Key Companies
- Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/metastatic-castration-resistant-prostate-cancer-pipeline-insight